MetLife is delivering record adjusted EPS, broad-based segment growth, and disciplined capital returns, but the stock is already near fair value. The report rates MET a Buy on improving earnings power and diversified insurance exposure.
MetLife (MET) offers a balanced medium-term investment case built on improving earnings, a diversified insurance platform, disciplined capital returns, and a forward P/E of 11.1x. The central attraction is not a single product or a short-lived underwriting gain. It is the combination of Group Benefits, retirement solutions, international insurance, and asset management operating under the New Frontier strategy.
MetLife reported 3Q26 adjusted EPS of $2.78, adjusted earnings of $1.8B, and total revenue of $20.5B on Nov. 4, 2026. Adjusted EPS reached a quarterly record, while adjusted earnings rose from $1.6B in 2Q26. The latest quarter also produced $2.4B of net income, or $3.67 per share, supported by higher investment returns and broad segment growth.
The counterweight is valuation discipline. At a quoted price of $100.67, MET is close to the $107.63 analyst target, while its trailing P/E of 19.3x remains well above its forward P/E. The balance sheet is substantial but insurance liabilities make the current ratio of 0.7 and debt-to-equity ratio of 0.7 worth monitoring. The result is a Buy for moderate-risk investors seeking earnings growth and capital returns, rather than a deep-value setup.
MetLife is a New York-based financial services company with 46,000 employees and operations across insurance, annuities, employee benefits, and asset management. Its products serve corporations, employees, institutions, and individuals across the United States, Asia, Latin America, Europe, the Middle East, and Africa.
The 2025 10-K organizes the business into Group Benefits, Retirement and Income Solutions, Asia, Latin America, EMEA, and MetLife Investment Management. The portfolio combines capital-light fee and underwriting businesses with capital-driven retirement and spread businesses. That mix gives MET multiple ways to generate earnings, although it also exposes the company to mortality, longevity, credit, interest-rate, and investment-market risks.
Management's New Frontier plan focuses on extending leadership in Group Benefits, expanding retirement and income solutions, accelerating asset management, and growing in international markets. The stated strategy targets double-digit adjusted EPS growth, 15% to 17% adjusted ROE, a 100-basis-point reduction in the direct expense ratio, and more than $25B of free cash flow from 2025 through 2029.
Group Benefits remains the most visible franchise. It generated $523M of adjusted earnings in 3Q26, up 15% year over year. The segment covers group life, dental, disability, accident and health, vision, and related employer benefit services. Its earnings combine recurring employer relationships with underwriting performance, making the segment a useful test of MetLife's pricing and claims discipline.
Retirement and Income Solutions produced $413M of adjusted earnings in 3Q26. The result declined 6% on a reported basis but increased 12% excluding notable items. RIS includes pension risk transfers, institutional income annuities, structured settlements, longevity reinsurance, stable value products, and funded reinsurance. The business benefits from retirement demand, but investment spreads and pension risk transfer volumes remain important swing factors.
Asia was the strongest large international contributor, generating $602M of adjusted earnings in 3Q26, up 11% reported and 14% in constant currency. Latin America produced $268M, up 45%, while EMEA generated $108M, up 24%. These results show the value of geographic diversification, although currency movements and local economic conditions affect reported results.
MetLife Investment Management generated $57M of adjusted earnings in 3Q26, up 9%. MIM had approximately $748B of assets under management at June 30, 2026, including a $7B sequential increase in institutional client assets during 2Q26. The PineBridge acquisition adds capabilities and fee revenue, but MIM's earnings contribution remains smaller than the insurance segments.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Group Benefits is MetLife's flagship product platform because it links employer distribution, recurring premiums, claims administration, and a broad product suite. The company offers life, disability, dental, vision, accident and health, paid family and medical leave, voluntary benefits, pet insurance, legal plans, and identity theft coverage. A broad bundle raises the value of the employer relationship and gives MetLife more opportunities to cross-sell.
In 2Q26, Group Benefits adjusted earnings rose 25% to $503M. The Group Life mortality ratio was 79%, better than the 83% to 88% annual target range, while year-to-date sales rose 9%. Management also reported double-digit sales growth in disability and voluntary products, with particular strength in accident and health.
The main caution is that favorable mortality is not a permanent margin assumption. Management said roughly two points of 2Q26 mortality favorability came from prior-period development and lower claim severity, with moderation already visible in July data. That makes the 3Q26 Group Benefits result more encouraging because adjusted earnings still reached $523M, but it also argues against capitalizing the 79% mortality ratio as a permanent earnings baseline.
MetLife's competitive advantage rests on scale, employer relationships, underwriting data, investment expertise, and product breadth. The two-part New Frontier model is strategically important. Capital-light businesses such as Group Benefits, Latin America, EMEA, and asset management generate fee and underwriting income, while retirement and spread businesses deploy the balance sheet against long-duration liabilities.
Artificial intelligence is becoming an operating tool rather than a marketing slogan. Management tied AI to the volume of policies, service interactions, and claims that MetLife handles each day. The company also said it monitors model usage and token costs under the same return standards applied to other investments. That discipline matters because the direct expense ratio was 12.1% in 2Q26 despite an approximately 50-basis-point expense impact from PineBridge.
MIM provides a second innovation path by converting internally originated assets and third-party capital into fee-based investment management opportunities. PineBridge expands that platform, while the $748B AUM base gives MetLife a meaningful institutional operating footprint. The advantage is durable when integration adds revenue and margin without forcing the company into transformational acquisitions.
For an insurer, the operating chain runs from product design and distribution to underwriting, claims handling, reinsurance, and investment management. MetLife's operating model spans employer and institutional channels, individual products, international distribution, and a large general account. The model depends on accurate pricing, efficient service, prudent reserves, and disciplined asset allocation rather than on physical inventory.
Execution was strong in 2Q26. The direct expense ratio was 12.1%, matching the full-year target at that point, and management cited productivity gains from AI and other technologies. In 3Q26, the ratio excluding notable items and pension risk transfers was 11.9% and was described as on track for the yearly target. This is meaningful because expense control supports earnings even when investment income or claims experience fluctuate.
Capital deployment is another operating capability. MetLife returned more than $1.1B to shareholders in 2Q26, repurchased approximately $700M of common shares, and announced a new $3B repurchase authorization. Holding company cash and liquid assets totaled $3.4B at June 30, 2026, within the stated $3B to $4B target buffer.
MetLife operates in a large but mature market. Swiss Re estimated global life insurance premiums at $3.1T in 2024 and projected $4.8T by 2035. The growth opportunity is uneven: mature markets emphasize retirement income, employee benefits, and capital efficiency, while emerging markets offer greater room for protection, savings, and health products.
Employer benefits remain a particularly important market. MetLife's investor-day materials cited approximately 60% of employers expanding benefits through the workplace and top-20 broker market share rising from 61% in 2019 to 71% in 2022. Broker consolidation raises the value of scale, product breadth, technology, and service quality.
Technology is changing distribution and claims administration. Gartner identifies AI, automation, legacy modernization, and data-driven engagement as major life insurance technology priorities. MetLife's policy and claims volume gives the company a large data base for applying automation, while its existing employer relationships provide distribution that newer digital entrants must build from scratch.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
MetLife serves several customer groups. Employers purchase group life, disability, dental, vision, accident, health, paid leave, and administrative services. Employees and individuals use protection, savings, annuity, legal, pet, and supplemental products. Institutions purchase pension risk transfers, structured settlements, longevity solutions, stable value products, and asset management services.
The customer relationship is often long duration. Employer benefit programs renew over multiyear cycles, while retirement and annuity products can remain on the balance sheet for decades. That creates switching friction, but it also raises the cost of pricing mistakes and service failures. Management described Group Life renewals as running on a three-to-five-year cycle, which gives pricing actions time to work but slows the correction of adverse trends.
International customers add growth and diversification. In 2Q26, Asia sales rose 17% in constant currency, Latin America sales rose 9%, and EMEA sales rose 15%. These figures reflect demand across life, accident and health, retirement, savings, and credit insurance products.
MetLife competes with Prudential, New York Life, Unum, Aflac, Cigna, Aetna, Sun Life, and Symetra across group benefits, life, disability, accident, and health products. It also faces HealthEquity, Optum, Fidelity, and HSA Bank in health account solutions, plus Alight, Businessolver, and bswift in benefits administration.
MetLife's stated position is strongest in non-medical benefits. Investor-day materials cited positions of number one in life, number two in disability, number two in dental, number one in vision, and number one in voluntary benefits among its cited competitive set. The same materials showed Group Benefits PFO growth of 6.4% CAGR versus 4.1% for the peer group over the cited period.
The competitive test is moving beyond price. Employer clients increasingly value consolidated administration, digital service, financial strength, claims performance, and a broad product menu. MetLife's scale and distribution are advantages, while broker concentration, health cost inflation, and technology investment keep pressure on margins. The company has stated that any M&A in Group Benefits or asset management must add complementary capabilities and clear a high value-creation bar.
Interest rates are central to MetLife's earnings because the company invests against long-duration insurance liabilities. Higher rates support new-money yields and retirement product economics, while rate moves also affect derivatives, asset values, reserves, and capital. In 3Q26, MetLife reported $551M of after-tax net derivative gains tied to embedded derivatives associated with ceded reinsurance as U.S. rates rose.
Investment spread performance remains a direct macro transmission channel. In 2Q26, total investment spread was 97 basis points, below the 100 to 120 basis-point guidance range, while core spread excluding variable investment income was 100 basis points. Private equity returns were a drag during that quarter, showing why a strong underwriting quarter does not eliminate market sensitivity.
Demographics support retirement income demand, longevity reinsurance, and protection products. International operations add currency and regulatory exposure across Asia, Latin America, and EMEA. The company's diversification across those markets reduces dependence on one economy, but it also makes local capital rules, political decisions, currency movements, and consumer affordability part of the risk profile.
MetLife’s current ratio of 0.7 and debt-to-equity ratio of 0.7 reflect a sizable insurance balance sheet that supports growth but deserves monitoring.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →3Q26 adjusted EPS hit a quarterly record of $2.78 as adjusted earnings rose to $1.8B and revenue reached $20.5B.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management is targeting double-digit adjusted EPS growth, 15% to 17% adjusted ROE, and more than $25B of free cash flow from 2025 through 2029.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $100.67, MetLife trades near the $107.63 analyst target and at 11.1x forward earnings, leaving limited upside from current levels.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The stock sits close to the $107.63 fair value mark, with the report’s Buy call reflecting earnings momentum rather than deep-value upside.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →MetLife is executing from a position of operating momentum. The company delivered record 3Q26 adjusted EPS, broad adjusted earnings growth, $18.1B of 2025 free cash flow, and a new $3B repurchase authorization. Group Benefits, Asia, Latin America, EMEA, and MIM all contributed to the latest earnings advance.
The investment case still requires discipline. MetLife remains exposed to interest rates, credit markets, mortality, longevity, currency, and regulatory conditions. With the stock near the $107.63 consensus target, the best risk-adjusted posture is a Buy rather than an aggressive chase. The combination of recurring premiums, retirement demand, international growth, asset management scale, and capital returns gives MET a credible path to compound shareholder value as long as management maintains its current execution standard.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
MetLife, Inc. (MET) gains 3.3% after reporting earnings beats, lifting shares as investors react to stronger-than-expected results and improved sentiment.
The MBA 30-year fixed mortgage rate slipped to 7.30%, its lowest level since September, but applications still fell 1.2%. Purchase demand weakened, refinancing remained depressed, and more borrowers turned to adjustable-rate loans as affordability stayed strained.
October’s U.S. services surveys showed expansion remained intact, but new orders and business activity cooled while prices paid stayed elevated. The split signals a slower economy with persistent inflation pressure, reinforcing the Federal Reserve’s case for keeping policy restrictive for longer.